Track Albireo Pharma's common stock ($20M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
Albireo Pharma (ALBO) currently reports a common stock of $20M as of September 2022. That compares with $19M in the prior-year period — up 2.1% year over year. Use the charts on this page to explore Albireo Pharma's common stock history and peer comparisons.
Albireo Pharma's common stock increased from $19M to $20M — a 2.1% year-over-year increase (period ending September 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Albireo Pharma reported $20M in common stock as of September 2022. That compares with $19M in the prior-year period — up 2.1% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current common stock of $20M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Albireo Pharma, and consider following ALBO for alerts when major investors trade the stock.
Albireo Pharma is classified in the Healthcare sector. On common stock, it currently shows $20M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ALBO with unrelated industries.